1. B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY. (5th April 2022) Authors: Rodriguez-Otero, P; Dholaria, B; Askari, E; Reece, D; van de Donk, N; Chari, A; Goldschmidt, H; Krishnan, A; Martin, T; Mateos, M; Morillo, D; Rodriguez, C; Rosinol, L; San-Miguel, J; Balari, A; Wäsch, R; Weisel, K; Verona, R; Lin, S; Prior, T Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS. (5th April 2022) Authors: Mateos, M; Hari, P; Bahlis, N; Chari, A; van de Donk, NWCJ; Dholaria, B; Garfall, AL; Goldschmidt, H; Kortüm, KM; Krishnan, A; Martin, T; Morillo, D; Oriol, A; Reece, D; Rodriguez, C; Rodríguez-Otero, P; San-Miguel, JF; Usmani, SZ; Verona, R; Lin, SXW Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL. (5th April 2022) Authors: Dimopoulos, MA; Oriol, A; Nahi, H; San-Miguel, J; Bahlis, NJ; Usmani, SZ; Rabin, N; Orlowski, RZ; Suzuki, K; Plesner, T; Yoon, SS; Ben Yehuda, D; Richardson, PG; Goldschmidt, H; Reece, D; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗